Galectin Therapeutics Inc. (GALT)
After hours:
| Previous close | 3.1400 |
| Open | 3.1800 |
| Bid | 3.2100 x 100 |
| Ask | 3.2700 x 100 |
| Day's range | 3.1500 - 3.2600 |
| 52-week range | 1.2800 - 4.2700 |
| Volume | |
| Avg. volume | 184,454 |
| Market cap | 199.949M |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today re
- GlobeNewswire
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. Detailed information about the presentation is below. H.C. Wainwright 2nd Annual BioConnect Investor Conference Format: Fireside chat Date and time: May 20, 2024 at 4:00 PM ET Location: Nasdaq World Headquarters,
- GlobeNewswire
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosisFifth positive recommendation further supports favorable tolerability and safety profile of belapectinInterim Phase 2b efficacy readout anticipated in Q4 2024 NORCROSS, Ga., April 09, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of
